PARIS—Biotechnology company ABIVAX has reported that top-line results from the first cohort of its Phase 2a trial, ABX464-005, show that ABX464 significantly reduced the HIV viral reservoir in blood in HIV patients, confirming the reduction seen in the previous Phase 2a trial. In this cohort, 11 HIV patients received 150 mg ABX464 for 28 days, in addition to their antiretroviral treatment. Two patients discontinued due to grade 1/2 adverse events and nine completed the study, eight of which saw a decrease in HIV DNA in peripheral blood CD4+ T cells between day 0 and day 28. The median for those nine patients dropped from 191 copies/million CD4+ T cells to 116 copies/million CD4 + T cells, a statistically significant decrease. Recruitment for the second cohort is underway.